title: Targeted norfloxacin is active in vivo against persistent Mycobacterium bovis BCG.
authors.affiliation: Groupe de Pharmacocinétique des Prodrogues et Conjugués Macromoléculaires (INSERM), CRBA-UMR 5473 CNRS, Faculté de Pharmacie,15 avenue Charles Flahault, BP 14491, 34093 Montpellier cedex 5, France.
authors.forename: D
authors.initials: D
authors.lastname: Domurado
authors.forename: A-M
authors.initials: AM
authors.lastname: Balazuc
authors.forename: M
authors.initials: M
authors.lastname: Lagranderie
authors.forename: P
authors.initials: P
authors.lastname: Pescher
authors.forename: P
authors.initials: P
authors.lastname: Chavarot
authors.forename: E
authors.initials: E
authors.lastname: Roseeuw
authors.forename: V
authors.initials: V
authors.lastname: Coessens
authors.forename: S
authors.initials: S
authors.lastname: Stern
authors.forename: E
authors.initials: E
authors.lastname: Schacht
authors.forename: G
authors.initials: G
authors.lastname: Marchal
mesh_terms: D000818:Animals; D051379:Mice; D008810:Mice, Inbred C57BL; D009163:Mycobacterium bovis / Q000187:drug effects*; D009643:Norfloxacin / Q000627:therapeutic use*; D011355:Prodrugs / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D011355:Prodrugs; D009643:Norfloxacin